Author Archives : Birgit Rogell

Home  >>  Author : Birgit Rogell

Hummingbird Diagnostics GmbH and Saarland University Collaborate in Early Disease Detection Based on Molecular Markers

On November 14, 2017, Posted by , In Allgemein,News,Press Releases, With Kommentare deaktiviert für Hummingbird Diagnostics GmbH and Saarland University Collaborate in Early Disease Detection Based on Molecular Markers

miRNA Experts Sign Framework Agreement HEIDELBERG and SAARBRÜCKEN, November 14, 2017 – Hummingbird Diagnostics GmbH, specialized in early disease detection using molecular markers derived from blood, and Saarland University agreed on a comprehensive framework agreement regarding an expanded collaboration in the field of molecular diagnostics. The work aims at the…

Heidelberg University: Distant Relatives: TOR Protein Regulates Cell Growth in Plants and Animals

On November 10, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Heidelberg University: Distant Relatives: TOR Protein Regulates Cell Growth in Plants and Animals

Plant researchers study gene which – if out of control – can contribute to cancer spread Two such different organisms as plants and humans developed from a common precursor cell. Traces of this over one-billion-year kinship remain anchored in the genetic material of both organisms. An international team of plant…

Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases

On November 10, 2017, Posted by , In News,Press Releases, With Kommentare deaktiviert für Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases

Collaboration and licensing agreement focused on investigating up to three targets and has a potential transactional value of up to EUR 307 million, excluding royalties Expands Boehringer Ingelheim’s comprehensive R&D programme in non-alcoholic steatohepatitis (NASH) and fibrotic liver disease with innovative novel treatment modalities Leverages MiNA’s leading expertise in RNA…

BioRN Annual Conference 2017 – Joint Forces for Future Innovations

On November 10, 2017, Posted by , In Allgemein,Press Releases, With Kommentare deaktiviert für BioRN Annual Conference 2017 – Joint Forces for Future Innovations

During the BioRN Annual Conference 2017 on October 24, titled “Revolution through Convolution – combining medtech, biotech and digital health to promote health science in our region”, about 120 participants came together from the BioRN Cluster and from the national and international life-science industry, among them representatives of the “Health…

DKFZ: A vaccine against cervical cancer for poor countries

On November 10, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für DKFZ: A vaccine against cervical cancer for poor countries

A novel vaccine against cancer-causing human papillomaviruses (HPV) is intended to help raise vaccination rates especially in developing countries. To this end, scientists from the German Cancer Research Center (DKFZ) in Heidelberg are developing a completely new vaccination concept based on a low-cost vaccine that protects from almost all known…

DKFZ: Misregulated protein breakdown promotes leukemias and brain cancer

On November 9, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für DKFZ: Misregulated protein breakdown promotes leukemias and brain cancer

An enzyme that is responsible for the breakdown of specific amino acids in food plays a key role in the development of leukemias and brain cancer, scientists from the German Cancer Research Center (DKFZ) in Heidelberg have now reported in Nature. The researchers have hence discovered a surprising link between…

Roche: FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation

On November 8, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Roche: FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation

Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease (ECD), a rare blood disease Approval based on data from a basket study, which enrolls participants across multiple diseases based predominantly on genetic profile Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has…

Roche: FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer

On November 8, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Roche: FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer

FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer Approval based on phase III results that showed Alecensa extended the average time that people lived without their disease worsening compared to crizotinib Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US…

DKFZ: Rare pancreatic cancer reveals targets for therapy

On November 8, 2017, Posted by , In News,Press Releases, With Kommentare deaktiviert für DKFZ: Rare pancreatic cancer reveals targets for therapy

Scientists from the German Cancer Research Center (DKFZ) have conducted comprehensive molecular analyses of a rare type of pancreatic cancer. They have discovered a variety of cellular alterations that can be targeted by drugs that are already available and in part even already approved for therapy. Malignant growths in the…

Fraunhofer IGB: Faster diagnosis of sepsis pathogens

On November 3, 2017, Posted by , In Press Releases, With Kommentare deaktiviert für Fraunhofer IGB: Faster diagnosis of sepsis pathogens

Microbial pathogens can be diagnosed unambiguously and within just 24 hours by means of high-throughput sequencing of their genetic makeup and special bioinformatics evaluation algorithms. Fraunhofer researchers have validated this in a clinical study with sepsis patients. The researchers present the NGS diagnosis platform at Medica in Düsseldorf from November…